Showing results (121-130 of 177) with videos related to

Sort By:
Pageof 18
Japanese Journal of Clinical Oncology|October 6, 2025
Protocol summary of a randomized controlled phase III trial for confirming the superiority of local radiotherapy for prostate cancer patients with high-volume metastasis sensitive to hormonal therapy: the JCOG2011 (HimeRT study)Naoki Terada, Keiji Nihei, Rihito Aizawa, et al.
BMC Urology|September 14, 2022
Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)-a prospective single-arm interventional studyMikio Sugimoto, Takuma Kato, Yoichiro Tohi, et al.
The Journal of Urology|August 21, 2019
Diagnostic Impacts of Clinical Laboratory Based p2PSA Indexes on any Grade, Gleason Grade Group 2 or Greater, or 3 or Greater Prostate Cancer and Prostate Specific Antigen below 10 ng/mlKazuto Ito, Akira Yokomizo, Shoji Tokunaga, et al.
International Journal of Clinical Oncology|July 31, 2024
Long-term outcomes of the first prospective study of active surveillance for prostate cancer in JapanTakuma Kato, Hiromi Hirama, Toshiyuki Kamoto, et al.
International Journal of Clinical Oncology|March 25, 2026
Prognostic value of the modified Glasgow Prognostic Score and Prognostic Nutritional Index in prostate cancer treated with cabazitaxelTakuma Kato, Yoichiro Tohi, Atsushi Takamoto, et al.
World Journal of Urology|May 17, 2017
Role of lymph node dissection during radical nephroureterectomy for upper urinary tract urothelial cancer: multi-institutional large retrospective study JCOG1110AJunichi Inokuchi, Kentaro Kuroiwa, Yoshiyuki Kakehi, et al.
European Urology Oncology|November 5, 2025
Prostate-specific Antigen and Objective Response Analyses in PROpel: Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone as First-line Therapy for Metastatic Castration-resistant Prostate CancerFred Saad, Andrew J Armstrong, Mototsugu Oya, et al.
European Urology|December 24, 2019
Salvage Radiotherapy Versus Hormone Therapy for Prostate-specific Antigen Failure After Radical Prostatectomy: A Randomised, Multicentre, Open-label, Phase 3 Trial (JCOG0401)†Akira Yokomizo, Masashi Wakabayashi, Takefumi Satoh, et al.
International Journal of Clinical Oncology|February 14, 2025
Characteristics of patients with metastatic renal cell carcinoma who do not respond to axitinib treatmentKojiro Ohba, Takahiro Osawa, Takahiro Kojima, et al.
The Journal of Urology|June 29, 2019
Impact of Previous, Simultaneous or Subsequent Bladder Cancer on Prognosis after Radical Nephroureterectomy for Upper Urinary Tract Urothelial CarcinomaKentaro Kuroiwa, Junichi Inokuchi, Hiroyuki Nishiyama, et al.
Pageof 18